Overview

Titan Pharmaceuticals, Inc. is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating  a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. 

ProNeura consists of a small, semi-rigid, flexible implant made from a mixture of EVA (ethylene-vinyl acetate) and a drug substance. The resulting product is a solid matrix implant that is placed subcutaneously, normally in the inner part of the upper arm, in a simple office procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician’s assistants in a HCP’s office or other clinical setting.

Titan’s first product based on its ProNeura technology was Probuphine® (buprenorphine) implant, which was approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine, In October 2020, Titan announced its decision to discontinue selling its Probuphine implant in the U.S. and wind down its commercialization activities, and to pursue a plan that will enable it to focus on its ProNeura-based product development programs. For additional information regarding Probuphine, click here.

Learn More

ProNeura® is a Proprietary, Long-Term, Continuous Drug Delivery Platform

The ProNeura long-term, continuous drug delivery platform is intended for treating chronic diseases for which maintaining non-fluctuating medication levels may offer advantages over other routes of administration.

Learn More About ProNeura

Product Pipeline

Kappa Opioid Receptor Agonist (TP-2021) Implant

for the treatment of moderate-to-severe chronic pruritus

More About Kappa Opioid Receptor Agonist (TP-2021) Implant

Product Pipeline

Nalmefene Implant

for the prevention of relapse in OUD patients following detoxification from opioids

More About Nalmefene Implant

Intellectual Property

Titan has a broad intellectual property portfolio, with issued patents and patent applications covering formulations, processes and methods related to the ProNeura® technology platform for the treatment of certain chronic diseases, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. These include implantable products in development for the prevention of opioid relapse following detoxification from opioids, and for the treatment of moderate-to-severe chronic pruritus.

View IP Portfolio

Leadership

Titan Pharmaceuticals' executive team has more than 75 years of collective experience in the pharmaceutical industry.

Latest News

November 8, 2021
Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021

SOUTH SAN FRANCISCO, Calif., Nov. 8, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, in a presentation given today at the Society for Neuroscience 2021 Meeting, Ben Land, Ph.D., Research Assistant Professor at the University of Washington's Department of Pharmacology, reported additional positive data from an

Read Press Release